Analysis of the factors influencing the survival time of patients with sarcomatoid renal cell carcinoma

被引:3
|
作者
Wang, Yu-Sheng [1 ]
Shuang, Wei-Bing [1 ]
Yin, Ke-Qiang [1 ]
Tong, Xu-Nan [1 ]
Xia, Man-Cheng [1 ]
Yang, Hao-Sen [1 ]
机构
[1] Shanxi Med Univ, Hosp 1, Dept Urol, 85 Jiefang Rd, Yingze 030001, Shanxi, Peoples R China
关键词
sarcomatoid renal cell carcinoma; survival time; survival analysis; Cox proportional hazards model; Kaplan-Meier estimate; log-rank test; PROGNOSTIC-FACTOR; SYSTEMIC THERAPY; DIFFERENTIATION; IMMUNOTHERAPY; NEPHRECTOMY; GEMCITABINE;
D O I
10.3892/mco.2019.1900
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The aim of the present study was to identify the factors influencing the survival time of patients with sarcomatoid renal cell carcinoma (SRCC). Between January 2000 and September 2017, a total of 21 patients were enrolled, all of whom were diagnosed with SRCC. In total, eight prognostic factors were analyzed using the Kaplan-Meier estimator, a log-rank test and Cox's proportional hazards model. The log-rank test results revealed that there was a significant association between the proportion of sarcoma elements and survival time of patients with SRCC (P<0.05). In addition, there was a significant association between post-operative drug treatment and SRCC survival time (P<0.05). The results of the Kaplan-Meier estimate demonstrated that the survival curve of post-operative drug treatment was significantly greater compared with the survival curve of patients who did not undergo drug treatment (P<0.05). The survival curve of patients with a proportion of sarcoma elements <50% was significantly greater compared with the survival curve of patients with a proportion of sarcoma elements >= 50% (P<0.05). Furthermore, the Cox's proportional hazards model revealed that the mortality risk in post-operative patients without drug treatment was 5.822 times greater compared with that of patients with drug treatment (P<0.05). Mortality risk in patients with a proportion of sarcoma elements >= 50% was 4.682 times higher compared with that of patients with sarcoma elements <50% (P<0.05). Finally, post-operative drug therapy was revealed to be a protective factor which significantly affected the survival time of patients with SRCC [risk ratio (RR)=0.172], in addition to the proportion of sarcoma elements >= 50% (RR=4.682). In conclusion, drug therapy should be promoted upon patient diagnosis with SRCC and attention should be given to the proportion of sarcomatoid components.
引用
下载
收藏
页码:405 / 410
页数:6
相关论文
共 50 条
  • [1] Prognostic factors and survival of patients with sarcomatoid renal cell carcinoma
    Mian, BM
    Bhadkamkar, N
    Slaton, JW
    Pisters, PWT
    Daliani, D
    Swanson, DA
    Pisters, LL
    JOURNAL OF UROLOGY, 2002, 167 (01): : 65 - 70
  • [2] Analysis of Clinicopathological Factors Influencing Survival in Patients with Renal Cell Carcinoma and Venous Tumor Thrombus
    Zapala, Lukasz
    Sharma, Sumit
    Kunc, Michal
    Zapala, Piotr
    Klacz, Jakub
    Korczynski, Piotr
    Lipowski, Michal
    Pozniak, Michal
    Suchojad, Tomasz
    Drewa, Tomasz
    Matuszewski, Marcin
    Radziszewski, Piotr
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (17)
  • [3] Survival outcomes in sarcomatoid renal cell carcinoma
    Al-Juhaishi, Taha
    Alder, Laura
    Paul, Asit K.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [4] PERCENTAGE OF SARCOMATOID HISTOLOGY IS ASSOCIATED WITH SURVIVAL FOR PATIENTS WITH RENAL CELL CARCINOMA
    Man, Amy
    Koehne, Elizabeth
    Patel, Hiten
    Aragao, Alessa
    Flanigan, Robert
    Gorbonos, Alex
    Gupta, Gopal
    Woods, Michael
    Picken, Maria
    Quek, Marcus
    JOURNAL OF UROLOGY, 2021, 206 : E811 - E811
  • [5] Factors influencing survival in acinic cell carcinoma: A retrospective survival analysis of 2061 patients
    Biron, Vincent L.
    Lentsch, Eric J.
    Gerry, Daniel R.
    Bewley, Arnaud F.
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2015, 37 (06): : 870 - 877
  • [6] A survival analysis of sarcomatoid renal cell carcinoma (sRCC) - a single institute experience
    Gaddy, Jacquelyne
    Kothari, Shalin
    Muppidi, Monica
    Bakhribah, Hatoon
    Wang, Katy
    George, Saby
    BJU INTERNATIONAL, 2016, 118 : 25 - 25
  • [7] Clinicopathologic features and prognostic factors in patients with renal cell carcinoma with sarcomatoid differentiation
    Zhao, Yuan
    Chen, Hong
    Xie, Yan
    Zhang, Chuanhong
    Hou, Yirui
    Jin, Mulan
    APMIS, 2020, 128 (05) : 378 - 386
  • [8] Sarcomatoid renal cell carcinoma: Does stage impact survival?
    Blum, Kyle A.
    DiNatale, Renzo
    Sanchez, Alejandro
    John, Nirmal T.
    Axler, Eden
    Ghanaat, Mazyar
    Kashan, Mahyar
    Becerra, Maria
    Russo, Paul
    Coleman, Jonathan
    Tickoo, Satish
    Hakimi, A. Ari
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [9] Sarcomatoid renal cell carcinoma: MRI features and their association with survival
    Monica Cheng
    Cihan Duzgol
    Tae-Hyung Kim
    Soleen Ghafoor
    Anton S. Becker
    Pamela I. Causa Andrieu
    Natalie Gangai
    Hui Jiang
    Abraham A. Hakimi
    Hebert A. Vargas
    Sungmin Woo
    Cancer Imaging, 23
  • [10] Sarcomatoid renal cell carcinoma: MRI features and their association with survival
    Cheng, Monica
    Duzgol, Cihan
    Kim, Tae-Hyung
    Ghafoor, Soleen
    Becker, Anton. S. S.
    Andrieu, Pamela. I. Causa I.
    Gangai, Natalie
    Jiang, Hui
    Hakimi, Abraham. A. A.
    Vargas, Hebert. A. A.
    Woo, Sungmin
    CANCER IMAGING, 2023, 23 (01)